Akebia Expects To Resubmit NDA For Vadadustat As Treatment For Anemia Due To CKD In Adult Patients On Dialysis In Q3 2023
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics plans to resubmit its New Drug Application (NDA) for Vadadustat, a treatment for anemia due to Chronic Kidney Disease (CKD) in adult patients on dialysis, in Q3 2023.
August 10, 2023 | 9:50 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Akebia's resubmission of its NDA for Vadadustat could potentially lead to a positive impact on its stock price, depending on the market's perception of the drug's potential.
The resubmission of the NDA for Vadadustat indicates Akebia's confidence in the drug's potential. If approved, it could provide a significant revenue stream for the company, which would likely be reflected in its stock price. However, the impact is not immediate as the resubmission is planned for Q3 2023.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100